参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Neuroendocrine and Adrenal Tumors Version 1.2019 — March 5,2019.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Hope TA,Bergsland EK,Bozkurt MF,et al.Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.J Nucl Med 2018, 59:66-74.
4.Dasari A,Shen C,Halperin D,et al.Trends in the Incidence,Prevalence,and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.JAMA Oncol 2017, 3:1335-1342.
5.Sadowski SM,Neychev V,Millo C,et al.Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.J Clin Oncol 2016, 34:588-596.
6.Ayati N,Lee ST,Zakavi R,et al.Long-Acting Somatostatin Analog Therapy Differentially Alters (68)Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.J Nucl Med 2018, 59:223-227.
7.Righi L,Gatti G,Volante M,et al.Lung neuroendocrine tumors:pathological characteristics.J Thorac Dis 2017, 9:S1442-S1447.
8.Deppen SA,Liu E,Blume JD,et al.Safety and Efficacy of 68Ga- DOTATATE PET/CT for Diagnosis,Staging,and Treatment Management of Neuroendocrine Tumors.J Nucl Med 2016, 57:708-714.
9.Bian D,Qi M,Hu J,et al.The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively.J Thorac Dis 2018, 10:1657-1669.
10.Kulke MH,Horsch D,Caplin ME,et al.Telotristat Ethyl,a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.J Clin Oncol 2017, 35:14-23.
11.Rimner A,Yao X,Huang J,et al.Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma-An Analysis of the International Thymic Malignancies Interest Group Retrospective Database.J Thorac Oncol 2016, 11:1785-1792.(https://www.daowen.com)
12.Daskalakis K,Karakatsanis A,Hessman O,et al.Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.JAMA Oncol 2018, 4:183-189.
13.Rinke A,Wittenberg M,Schade-Brittinger C,et al.Placebo-Controlled,Double-Blind,Prospective,Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID):Results of Long-Term Survival.Neuroendocrinology 2017, 104:26-32.
14.Ruszniewski P,Valle JW,Lombard-Bohas C,et al.Patientreported outcomes with lanreotide Autogel/Depot for carcinoid syndrome:An international observational study.Dig Liver Dis 2016, 48:552-558.
15.Fazio N,Buzzoni R,Delle Fave G,et al.Everolimus in advanced,progressive, well-differentiated,non-functional neuroendocrine tumors:RADIANT-4 lung subgroup analysis.Cancer Sci 2018, 109:174-181.
16.Pavel ME,Baudin E,Oberg KE,et al.Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome:final overall survival from the randomized,placebocontrolled phase 3 RADIANT-2 study.Ann Oncol 2017, 28:1569-1575.
17.Vinik AI,Wolin EM,Liyanage N,et al.Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect):A Randomized,Double-Blind, Placebo-Controlled Trial.Endocr Pract 2016, 22:1068-1080.
18.Lutetium Lu 177 dotatate ［package insert］.Millburn,NJ:Advanced Accelerator Applications USA,Inc.2018.
19.Yao JC,Guthrie KA,Moran C,et al.Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors:SWOG S0518.J Clin Oncol 2017, 35:1695-1703.
20.Caplin ME,Pavel M,Cwikla JB,et al.Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours:the CLARINET open-label extension study.Endocr Relat Cancer 2016, 23:191-199.
21.Fassnacht M,Dekkers O,Else T,et al.European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults,in collaboration with the European Network for the Study of Adrenal Tumors.Eur J Endocrinol 2018.